What's Hot
View all perspectives
David Liew drdavidliew
2 years ago
Can you put a bit of morphine intraarticularly inside an osteoarthritic knee and make it better?
Cute idea, no bingo.
I get that we're chasing better symptomatic solutions, but...
Don't do this.
ABST1833 #ACR22 @RheumNow https://t.co/pvsGx93eoU
David Liew drdavidliew
2 years ago
Erosive OA:
have we got anything disease-modifying?
Not much right now (read: nothing)
Denosumab 60mg q3mo for bone remodelling?
radiographic change, erosive jt development: real improvement
pain, function: zip at 48w, some at 96w?
Def worth more study!
ABSTL05 #ACR22 @RheumNow https://t.co/Yo9u5BlYYJ
Patricia Harkins DrTrishHarkins
2 years ago
PAN relapse risk ⬆️ in:
👉severe GI involvement
🧓>65y/o
👉skin necrotic lesions
PAN ⬆️ mortality wt:
👉AKI
🧓>65y/o
👉necrotic purpura
👉secondary PAN
Abst#2232 @RheumNow #ACR22
Akhil Sood MD AkhilSoodMD
2 years ago
Abstr #2196- COVID-19 outcomes in IMID dx in large US Hospital
vs Pre-Omicron
- ↑ COVID + rate (21.9% vs 7.9%)
- ↓ hospitalized (0.8% vs 3%) & death (1.8% vs 4.5%)
- Hospitalization & death > gen pop both pd.
-Age & comorbidities assoc w worse outcomes
@RheumNow #ACR22
David Liew drdavidliew
2 years ago
Biosimilar multi-switching in RA: is it an issue?
Switching back & forth between originator & biosimilar should create ideal conditions for immunogenicity or anti-drug Ab
This study: multi-switching vs no switching
No issues at all
Switch away in RA!
ABST1589 #ACR22 @RheumNow https://t.co/pGBF2BHp7y
Dr. John Cush RheumNow
2 years ago
We want to see how you are taking in #ACR22! Share your favorite pictures from ACR on Twitter and tag #RheumPix and #ACR22 and we'll re-tweet our favorite ones! https://t.co/ygfYol5Z3f
Dr. John Cush RheumNow
2 years ago
ACR2022 Topic Panels https://t.co/5gMfFS8maR
The last day was jammed with important reports and research including the late breaking abstracts.
Curcumin, the active constituent of turmeric extract, has increasingly been promoted as a potential rheumatoid arthritis therapy, but data presented at ACR22 suggests that even in ideal situations, it is unable to do any better than placebo in replacing conventional RA therapies.
A few things we know about opioids: use is common; it’s not efficacious in the treatment of spondyloarthritis; and, there is an opioid epidemic and its users are stigmatized. Abstract 0402 is a retrospective study that looked at patients with psoriatic arthritis or ankylosing spondylitis in the FORWARD databank. It sheds new light and leaves us with some food for thought
David Liew drdavidliew
2 years ago
@rheumecraig @RheumNow Absolutely. In this #ACR22 study, they did exclude anyone with deranged LFTs from this study and yet still two people in the turmeric arm got LFT derangement (vs zero in placebo). Sadly I don't think the turmeric salespeople are watching the LFTs.
Akhil Sood MD AkhilSoodMD
2 years ago
Abstr #2191 studies impact of maternal SLE on outcomes of children
Maternal SLE assoc w/ ↑ odds of
- SLE of children (HR 98.48, 95%CI:63.39-152.98)
- other AutoImm dx (HR 1.26, 1.02-1.57) (Hashimoto, JRA, IBD)
- Neurodev dx (1.35, 95%CI:1.15-1.57) (ADHD)
@RheumNow #ACR22
Dr. Rachel Tate uptoTate
2 years ago
UPA tx in prior TNFi tx PsA pts demonstrated consistent efficacy compared to the overall population in SELECT-PsA 2, regardless of number of prior anti-TNF therapies. Abs 2146 #ACR22 @RheumNow https://t.co/xnN4nvZ934 https://t.co/3S6ZzPvqVe
sheila RHEUMarampa
2 years ago
How to adjust for GC correction when dose >/= 7.5mg/d using FRAX?
Calculate FRAX then
🦴For MOF risk multiply by 1.15
🦴HF risk multiply by 1.2
= adjusted risk (%)
(Adjustment of FRAX accdg to GC dose from Kanis et al., OI 2011)
#ACR22 @RheumNow @Rheumarhyme @PhRheumaJr https://t.co/qap1fFhF0h
One of the enduring legacies of ACR 2022 for me will be the emphasis on polymyalgia rheumatica (PMR). Despite being highly inflammatory and relatively common, a remarkable paucity of trials have been run in this space. Read on for a quick PMR-roundup from the meeting!
Poster Hall